Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.
We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999-2004) was examined. Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and zoster ophthalmicus). The risk for OI was significantly higher in the first year of treatment (odds ratio [OR] 8; 95% confidence interval [CI] 2-50). Previous treatment with more than two immunosuppressive drugs was the only factor related to OI (OR 8.686; 95% CI 1.889-39.943). We identified the subset of patients treated with infliximab who had a higher risk for OI. The screening of latent infections is key to diminishing the incidence of these infections.
Garcia-Vidal
C
C
Hospital Mútua de Terrassa, University of Barcelona, Spain. carolgv75@hotmail.com
Rodríguez-Fernández
S
S
Teijón
S
S
Esteve
M
M
Rodríguez-Carballeira
M
M
Lacasa
J M
JM
Salvador
G
G
Garau
J
J
D000038:Abscess / Q000453:epidemiology / Q000209:etiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D015331:Cohort Studies; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology / Q000209:etiology; D006563:Herpes Zoster Ophthalmicus / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007107:Immune System / Q000187:drug effects; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000069285:Infliximab; D007898:Leishmaniasis, Visceral / Q000453:epidemiology / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000453:epidemiology / Q000209:etiology; D012307:Risk Factors; D018709:Statistics, Nonparametric; D014376:Tuberculosis / Q000453:epidemiology / Q000209:etiology
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab
Ann Rheum Dis. 2007 Dec;66(12):1610-5
17456528
Lancet. 2003 Nov 29;362(9398):1828-38
14654323
Vaccine. 2008 Jun 25;26(27-28):3528-33
18502006
Ann Rheum Dis. 2006 Feb;65(2):191-4
16014674
Arthritis Rheum. 2006 Aug;54(8):2368-76
16868999
Clin Infect Dis. 2005 Mar 1;40(5):756-9
15714425
Clin Infect Dis. 2007 Oct 1;45(7):826-36
17806046
Arthritis Rheum. 2004 Jun;50(6):1959-66
15188373
Arthritis Rheum. 2002 Sep;46(9):2294-300
12355476
Immunol Today. 1992 Apr;13(4):136-42
1374612
Arthritis Rheum. 2005 Jun;52(6):1766-72
15934089
N Engl J Med. 2001 Oct 11;345(15):1098-104
11596589
Gut. 2004 Sep;53(9):1363-5
15306601
Lancet Infect Dis. 2003 Mar;3(3):148-55
12614731
N Engl J Med. 1988 Jun 2;318(22):1423-31
3259286
J Rheumatol. 2007 May;34(5):952-7
17444589
Clin Infect Dis. 2007 Oct 1;45(7):837-45
17806047
Crit Care Clin. 2002 Oct;18(4):931-56
12418448
Medicine (Baltimore). 2005 Sep;84(5):291-302
16148729
Best Pract Res Clin Rheumatol. 2003 Apr;17(2):345-63
12787529
Arthritis Rheum. 2006 Feb 15;55(1):19-26
16463407
Clin Infect Dis. 2004 May 1;38(9):1261-5
15127338
Clin Gastroenterol Hepatol. 2004 Apr;2(4):309-13
15067625
Semin Arthritis Rheum. 2004 Feb;33(4):283-8
14978666
Clin Infect Dis. 2006 Nov 15;43(10):e95-100
17051484
Inflamm Bowel Dis. 2007 Nov;13(11):1450-1
17712837
Rheumatol Int. 1990;10(4):165-9
2259842